AI-Powered Fragrance Company Osmo Raises $70 Million in Series B Funding

Why It Matters

The funding validates investor confidence in AI‑enabled fragrance tech and could reshape how brands develop scents, shortening time‑to‑market and opening new diagnostic applications.

Key Takeaways

• $70M Series B led by Two Sigma Ventures
• New C-suite hires bring CPG and automotive expertise
• Expanding manufacturing to New Jersey by end‑2026
• AI “olfactory intelligence” targets indie brands and CPGs
• Plans include scent‑based health diagnostics

Pulse Analysis

The fragrance industry is undergoing a digital transformation as artificial intelligence moves from novelty to core capability. Osmo’s olfactory intelligence platform digitizes scent molecules, enabling rapid formulation and virtual testing that traditional perfumery cannot match. By securing a $70 million Series B, the company joins a small cohort of AI‑powered scent innovators, signaling that venture capital sees scalable revenue potential beyond niche boutique perfumes. This infusion of capital not only validates the technology but also positions Osmo to compete with legacy houses like Givaudan and DSM‑Firmenich on speed and customization.

Operationally, Osmo is converting its Manhattan office into a full‑scale manufacturing site in Elizabeth, New Jersey, a move that will centralize production and reduce logistics costs for its B2B clients. The recent hires—a former Unilever commercial chief, a Givaudan operations veteran, and a finance leader from Tesla—bring deep expertise in consumer packaged goods, fragrance chemistry, and high‑growth financial management. Their combined experience is expected to tighten Osmo’s supply chain, accelerate client onboarding, and expand the company’s service portfolio, from bespoke scent creation for indie brands to large‑scale rollouts for multinational CPGs.

Looking ahead, Osmo’s ambition to translate scent data into health‑care diagnostics could create a new market vertical, leveraging AI to detect disease markers through volatile organic compounds. While the broader AI boom faces skepticism and bubble concerns, the company’s focus on tangible, revenue‑generating B2B contracts provides a defensive moat. If Osmo can successfully commercialize both fragrance acceleration and diagnostic tools, it may set a precedent for how AI can monetize sensory data across consumer and medical sectors, reshaping industry economics for years to come.